134 results
POS AM
PBLA
Panbela Therapeutics, Inc.
29 Mar 24
Prospectus update (post-effective amendment)
5:08pm
by diversification. However, we lack and expect to continue to lack diversification, in terms of both the nature and geographic scope of our business … or other similar approvals. The cost and timing of additional clinical trials are highly dependent on the number of indications we pursue and the nature
8-K
EX-10.2
2oys 4ko8
29 Jan 24
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
6:21am
D
c22j yja0ay9p
5 Jan 24
Indefinite amount in equity / options, sold $2.00 mm, 2 investors
12:48pm
D
8w3p3ya
17 Nov 23
Indefinite amount in equity / options, sold $3.32 mm, 3 investors
5:10pm